Silibinin

DB09298InvestigationalSmall molecule

Silibinin is a flavonolignan with hepatoprotective effects used to treat toxic liver damage and as an adjunct in the management of chronic conditions such as cirrhosis and hepatitis. Silibinin is the major active constituent of silymarin, a standardized extract of the milk thistle seeds, containing a mixture of flavonolignans consisting of silibinin, isosilibinin, silicristin, silidianin and others.

Chemical structure of Silibinin
Primary indication
Currently being tested as a treatment of severe intoxications with hepatotoxic substances, such as death cap (Amanita phalloides) poisoning.Curator reviewed · 14 structured indications
Formula / weight
C25H22O10 · 482.441 g/mol (avg)
Also known as
Silibinin A · Silybin · Silybin A · Silymarin I

Resolves to

Structure
InChIKeySEBFKMXJBCUCAI-HKTJVKLFSA-NSMILES[H][C@@]1(OC2=C(O[C@@H]1CO)C=CC(=C2)[C@@]1([H])OC2=C(C(O)=CC(O)=C2)C(=O)[C@@H]1O)C1=CC(OC)=C(O)C=C1

What you can answer from here — as of July 17, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4TransportersSubstrate / inhibitor direction, not just membership
Listed above
299Drug interactionsStructured to mechanism, not free text
Sign in
70Clinical trialsPhase, status and sponsor resolved per trial
Sign in
14Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
3ContraindicationsEach with its own population and attribute set
Sign in
53Marketed productsAcross 4 countries and 34 labellers
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Silibinin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.

Create Account